Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects

Trial Profile

Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2012

At a glance

  • Drugs Gandotinib (Primary)
  • Indications Myeloproliferative disorders; Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 02 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top